<DOC>
	<DOCNO>NCT00560755</DOCNO>
	<brief_summary>Primary objective : To describe safety profile second dose ProQuad® manufacture rHA administer child second year life . Secondary objective : To describe safety profile first dose ProQuad® manufacture rHA administer child second year life</brief_summary>
	<brief_title>ProQuad® rHA Safety</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Healthy subject either gender , Age 12 22 month , Negative clinical history infection measles , mumps , rubella , varicella zoster , Informed consent form sign parent ( ) legal representative Parent ( ) legal representative able attend schedule visit subject understand comply study procedure Recent ( ≤ 3 day ) history febrile illness Prior receipt measles , mumps , rubella and/or varicella vaccination , either alone combination Recent ( ≤ 30 day ) exposure measles , mumps , rubella , varicella zoster Prior know sensitivity/allergy component vaccine Severe chronic disease , Blood dyscrasia , leukaemia , lymphomas type , malignant neoplasm affect haematopoietic lymphatic system Any severe thrombocytopenia coagulation disorder would contraindicate intramuscular injection Humoral cellular immunodeficiency , Current immunosuppressive therapy Family history congenital hereditary immunodeficiency Hereditary problem fructose intolerance Known personal history encephalopathy , seizure disorder progressive , evolve unstable neurological condition , Known active tuberculosis Recent ( ≤ 2 day ) tuberculin test schedule tuberculin test Visit 3 Receipt immunoglobulin bloodderived product past 150 day Receipt inactivate vaccine past 14 day Receipt live vaccine past 28 day</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>22 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prevention : measles , mumps , rubella varicella</keyword>
</DOC>